|Day Low/High||37.57 / 38.08|
|52 Wk Low/High||33.88 / 64.50|
Stocks in the health care sector seem to have no underpinnings whatsoever.
I'm talking about head-to-head comparisons of companies.
The debt-laden drugmaker needs to shore up cash, but a Salix sale might be too rash a move.
Prospective deals are hijacking an earnings-based focus on fundamentals.
British American Tobacco's $47 billion offer to purchase Reynolds American could face hurdles from shareholders as well as regulators.
Shares of Walgreens Boots Alliance were higher on Thursday after posting better-than-expected earnings for the fiscal fourth-quarter.
U.S. stocks accelerate losses throughout the morning as crude oil retreats from its highest level of the year.
It would block the early November rally you'd expect when this big event is, at last, past us.
Walgreens extends merger deadline with Rite Aid, and Telsa unveils its new product.
On Thursday, October 20, investors await quarterly results from American Airlines and a policy statement from the European Central Bank.
For starters, trouble for banks, drugs, energy and M&A.
U.S. stocks edged higher on Wednesday after a stream of positive earnings trickled in.
Walgreens is set to report quarterly results on Thursday ahead of the opening bell and TheStreet's Jim Cramer believes the drugstore chain should walk away from Rite Aid.
Investors will get a slew of earnings reports from major companies and a host of Federal Reserve speakers during the week of Oct. 17.
This year hasn't gone Target's way, but its smaller-store format is one way it quietly is working to build a competitive edge for the long haul.
Action Alerts PLUS holdings are preparing for a smartphone showdown, while fellow holding Walgreens could see a boost to earnings.
Rite Aid shares are up Thursday after posting second quarter earnings of $0.03 a share, a penny ahead of forecasts.
U.S. stocks rose on Thursday, fueled by the Federal Reserve's decision Wednesday to keep interest rates lower for longer.
Earnings and economic data are in focus for Thursday, September 22.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer isn't fond of how Rite Aid is being managed.
The recent selloff doesn't track the strong economics of the business.
McKesson is down 10 percent year-to-date due to the heated political debate over drug pricing but the stock is too cheap to ignore.
Disappointment over the ECB's inaction and uncertainty over the Fed's rate plans left markets rattled.
Oil stocks surge on EIA data, while Rite Aid and Walgreens continue to push their pending deal forward.
Shares of Kroger were lower Wednesday. The supermarket chain has emerged as a buyer for stores of Rite Aid.